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Background: Many candidate vaccine strategies against human immunodeficiency virus (HIV) infection are under
study, but their clinical development is lengthy and iterative. To accelerate HIV vaccine development optimised trial
designs are needed. We propose a randomised multi-arm phase I/II design for early stage development of several
vaccine strategies, aiming at rapidly discarding those that are unsafe or non-immunogenic.
Methods: We explored early stage designs to evaluate both the safety and the immunogenicity of four
heterologous prime-boost HIV vaccine strategies in parallel. One of the vaccines used as a prime and boost in the
different strategies (vaccine 1) has yet to be tested in humans, thus requiring a phase I safety evaluation. However,
its toxicity risk is considered minimal based on data from similar vaccines. We newly adapted a randomised phase II
trial by integrating an early safety decision rule, emulating that of a phase I study. We evaluated the operating
characteristics of the proposed design in simulation studies with either a fixed-sample frequentist or a continuous
Bayesian safety decision rule and projected timelines for the trial.
Results: We propose a randomised four-arm phase I/II design with two independent binary endpoints for safety
and immunogenicity. Immunogenicity evaluation at trial end is based on a single-stage Fleming design per arm,
comparing the observed proportion of responders in an immunogenicity screening assay to an unacceptably low
proportion, without direct comparisons between arms. Randomisation limits heterogeneity in volunteer characteristics
between arms. To avoid exposure of additional participants to an unsafe vaccine during the vaccine boost phase, an
early safety decision rule is imposed on the arm starting with vaccine 1 injections. In simulations of the design with
either decision rule, the risks of erroneous conclusions were controlled <15%. Flexibility in trial conduct is greater with
the continuous Bayesian rule. A 12-month gain in timelines is expected by this optimised design. Other existing designs
such as bivariate or seamless phase I/II designs did not offer a clear-cut alternative.
Conclusions: By combining phase I and phase II evaluations in a multi-arm trial, the proposed optimised design allows
for accelerating early stage clinical development of HIV vaccine strategies.
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Although several promising approaches to prevent hu-
man immunodeficiency virus (HIV) infection have been
put forth in the recent years [1-4], the development of a
prophylactic vaccine strategy remains a key goal in the
effort to end the HIV epidemic.
The main prophylactic HIV vaccine candidates currently
under study include subunit or epitope-based vaccines
with or without adjuvants, recombinant virus-vector
vaccines and deoxyribonucleic acid (DNA) vaccines.
The combination of different vaccines into heterologous
prime-boost strategies is today considered a promising
approach. Indeed, results of a phase IIB trial in Thailand
(RV144 trial), combining a virus-vector vaccine prime
with a subunit boost, showed a modest protective effect
of the tested HIV vaccine strategy [5]. HIV vaccine de-
velopment remains ongoing and too lengthy. For in-
stance, clinical development of the components of the
HIV vaccine strategy evaluated in the RV144 trial
started in the mid-1990s in Thailand, however the re-
sults of the aforementioned phase IIB trial only became
available in 2009. According to development timelines,
a confirmatory phase III trial with an improved vaccine
strategy is not projected to start before 2019 [6,7].
The fact that immunological correlates of protection
are not well understood has hampered HIV vaccine de-
velopment to date [8]. A protective vaccine effect can
currently not be predicted on the basis of vaccine-
induced immunogenicity markers. Since transition from
phase I/II to phase IIB/III trials can thus not rely on a
validated surrogate immunogenicity endpoint, and large
sample sizes and resources are required for later-stage
trials with HIV-acquisition endpoints (phase IIB/III), the
clinical development of HIV candidate vaccine strategies
is laborious. Phase I and II HIV vaccine trials usually in-
clude extensive immunogenicity assessments, measuring
both the humoral and cellular immune responses to vac-
cines with different markers and techniques. All of the
above complicates the decision to set up a large-scale
IIB/III trial, powered for an HIV-acquisition endpoint.
These constraints have resulted in only six HIV vaccine
phase IIB/III trials conducted so far, five of which
yielded disappointing results without any evidence for
protective vaccine effects [9-11].
Recently, calls for accelerated clinical development of
HIV vaccine strategies have been put forward, advocat-
ing the implementation of adaptive trial designs for this
purpose [12,13]. Indeed, numerous adaptive or multi-
stage clinical trial designs for different phases of clinical
development are available in the methodological litera-
ture. However, these designs were mainly devised for
cancer treatment trials, which differ from HIV vaccine
trials. In oncology, the patients who are enrolled in trials
suffer severe illness requiring treatment. Inefficaciousstrategies must thus be identified as soon as possible to
avoid harm. In contrast to oncology trials, including tri-
als for therapeutic cancer vaccines [14], the development
of prophylactic HIV vaccines targets a non-ill population
and thus necessitates specific design considerations.
Moreover, assessment of endpoints is clearer in oncology
trials both because of a higher incidence and more well-
defined surrogate endpoints, such as tumour response
criteria [15]. The application of adaptive trial designs to
HIV vaccine research is challenging given that numerous
immunogenicity endpoints without a definite hierarchy
are evaluated in phase II trials and that clinical develop-
ment plans should remain flexible enough to accommodate
new scientific knowledge. Thus, trial design optimisation
has rarely been considered in HIV vaccine research, yet as
the number of potential HIV vaccine strategies under de-
velopment increases it has become of greater interest [16].
Gilbert et al. proposed an adaptive phase IIB/III design
with an HIV-acquisition endpoint for mid- to late-stage
clinical development (phase IIB/III), which has yet to be
applied in practice [17]. For early-stage development,
Moodie et al. recommended a phase IB selection design in
2006 to prioritise among different candidate vaccine
strategies the one with the top-rank based on an im-
munogenicity endpoint. At that time, they considered
that knowledge about HIV vaccine immunogenicity was
too limited to select vaccine strategies using bounds based
on a theoretical response rate [18]. To date, although un-
derstanding of vaccine-elicited immune responses still re-
quires much more progress, this justification has evolved.
We now consider it purposeful to define an insufficient re-
sponse level in a widely used, validated immunogenicity
screening assay [19].
Currently, more than 20 ‘generic’ HIV candidate vac-
cines are in early clinical development [16]. Given that
generic candidates may be tested with different antigen
inserts, that combinations of different candidate vaccines
are evaluated and that strategies with the same combin-
ation may differ in terms of the timing of injections, the
number of potential vaccine strategies is large. Efficient
screening of potential strategies and decision making in
early stage development is thus crucial. In the present
article, we present an early-stage trial design, integrating
phases I and II to evaluate both safety and immunogen-
icity endpoints of several HIV vaccine strategies in paral-
lel and allowing for the rapid cessation of those with
insufficient safety or immunogenicity levels.
Methods
Motivating example
Our search for an optimised phase I/II HIV vaccine trial de-
sign was motivated by the clinical development plan of a
vaccine portfolio comprising three prophylactic HIV candi-
date vaccines, referred to herein as ‘vaccine 1’, ‘2’ and ‘3’.
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(MVA) virus) expressing HIV antigens, which has not
yet been evaluated in humans with the specific HIV in-
serts used. It therefore requires a phase I safety study be-
fore it can be administered to a larger number of
volunteers. However, the MVA vector with different HIV
and non-HIV inserts has already been studied in previ-
ous trials and has a good safety profile in humans
[20-26]. Minimal toxicity is thus expected for vaccine 1.
The tested target dose (1x108 plaque-forming units) corre-
sponds to the standard dose tested for MVA vaccinations
against smallpox [22,27] and to the dose selected in previ-
ous dose-escalation studies of MVA vectors with HIV and
non-HIV inserts [20,24,28,29]. No dose escalation is thus
planned for this vaccine in our development plan.
Vaccine 2 is a lipopeptide vaccine, including an equal-
weight mix of five synthetic HIV-1 peptides coupled to a
palmytoil tail (HIV LIPO-5). Vaccine 3 is a deoxyribo-
nucleic acid (DNA) vaccine, encoding for a multi-HIV
antigen. Both vaccines 2 and 3 have been studied previ-
ously in phase I and II trials and have a good safety rec-
ord [30-33].
In the clinical development plan of this vaccine portfo-
lio, the three vaccines are combined into four heterol-
ogous (that is, using different vaccines in the prime and
the boost phase) prime-boost strategies (Figure 1). Vac-
cine 3 is currently being considered only for use as a
prime vaccine component, and not as a boost [34].
In our clinical development plan, the aim of the phase
I evaluation of vaccine 1 at the target dose is to stop ad-
ministrations of this vaccine as soon as possible in caseFigure 1 Overview of the proposed multi-arm phase I/II design. Legenof a safety problem. The early stage of the phase II
evaluation aims at screening each of the four prime-
boost combinations for a minimum immunogenicity
level. Non-immunogenic or unsafe vaccine strategies
should be discarded as soon as possible. A ‘classical’ clin-
ical development scheme with several phase I and II tri-
als to address these objectives would be a lengthy
process. In order to accelerate the clinical development
and given the high likelihood of a good safety profile of
vaccine 1 similar to the one observed with different HIV
inserts, we sought to set up an optimised trial design
combining phases I and II for evaluation of the four
prime-boost strategies in parallel.
For the purpose of the present work, we defined an
‘optimised design’ as a trial design allowing for a gain in
timelines (and, if possible, in the number of trial partici-
pants) compared to separate phase I and II trials, while
remaining feasible and respecting the requirements out-
lined below.
Requirements for the optimised phase I/II vaccine trial
design
In searching for an optimised design appropriate for our
development plan, we imposed the following methodo-
logical requirements:
 First, a randomised multiple arm design is desirable
to ensure comparability of populations and unbiased
assessment of several vaccine strategies in parallel,
even if no direct statistical comparisons are made
between arms [35].d: W =week.
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immunogenicity and safety endpoints, assessed at
different time points, allowing for an early safety
decision rule to emulate the phase I evaluation of
vaccine 1 during the vaccine prime phase. The dose used
for vaccine 1 is considered well below the toxic dose.
 Third, endpoints for immunogenicity and safety are
not necessarily correlated, since severe vaccine-
related toxicity events and immunogenicity are likely
to be unrelated [36].
 Fourth, an important constraint of the design is the
fact that safety and immunogenicity outcomes are not
observed simultaneously, since the immunogenicity
measurements of all participants are planned in batch
at a central laboratory at the end of the trial to allow
for blinded assessments and to limit measurement
error due to time and batch effects.
 Fifth, data integration of phase I into phase II
evaluation should be possible to allow for an optimal
use of the collected data.
 Sixth, the trial design must be compatible with high
early accrual dynamics and with conduct as a multi-
centre trial. Prophylactic HIV vaccine trials enrol
healthy volunteers, a process that allows for better
planning and management of recruitment dynamics
than the enrolment of ill patients. To keep costs
low, a single call for volunteers is planned for our
trial. As previous vaccine trial recruitment studies
have shown that a ‘waiting time’ between the first
contact and enrolment may lead to a loss of interest
in participation [37], the time between the call for
volunteers and the start of the trial will be kept
short. Altogether, this is expected to result in high
early accrual dynamics.
 Lastly, a design without a control group was
favoured since HIV-specific immune responses
can be considered to be close to zero in healthy
volunteers at low risk of HIV infection, as attested
by immune response measurements in prophylactic
HIV vaccine trials at baseline or in a placebo arm
[20,21,38-40]. A vaccine strategy meeting the
immunogenicity endpoint can therefore be deemed
clearly distinct from a potential control group. Given
that the volunteers in the planned trial will have a
low-risk profile (restricted by the eligibility criteria)
and the fact that all participants will receive an
experimental vaccine strategy, we considered it
unlikely that differential risk behaviour during the trial
would have an impact on the immunogenicity endpoint.
A summary of these requirements is shown in the list
below:
▪ randomized multi-arm trial▪ evaluation of both efficacy and safety endpoints, with:
– early safety decision rule
– difference in timing of the evaluation between the
two endpoints
– assumption that toxicity events and efficacy are
likely unrelated
– efficacy outcome not observed in real-time
(measured in batch in central lab at end of the trial)
– data integration of phase I into phase II efficacy
evaluation
▪ compatibility with high early accrual dynamics and
with conduct as a multi-centre trial
▪ no control arm
Moreover, although not a formal design requirement, an
open-label design was preferred since the immunogenicity
endpoint can be measured objectively and laboratory staff
performing the measurements centrally will be blinded to
trial arm and time point. Although a blinded control
group would limit bias in the evaluation of safety, imple-
mentation of blinding is difficult in practice: indeed, blind-
ing would require the introduction of dummy vaccine
injections in each trial arm, since vaccination time points
during the prime phase vary between vaccine strategies
(Figure 1). Additional immunogenicity sampling time
points after each dummy shot would then be necessary for
maintaining blinding, requiring large amounts of blood.
Blinding participants and site staff was thus not pursued
for this trial design, but we acknowledge that a blinded
placebo control arm could be helpful for safety assess-
ments when feasible.
Search for the optimised design
We first searched the literature for existing trial designs
fulfilling the requirements outlined above in order to be
appropriate for application to early stage clinical HIV vac-
cine development. We performed a literature search in
Pubmed/Medline using the search terms (‘Clinical Trials,
Phase II as Topic’ [MAJR]) AND (‘Therapeutics/adverse
effects’ [MeSH] OR safety OR toxicity). In addition, the re-
view and manual of phase II designs by Brown et al. were
used to identify potential designs for our context [41].
Moreover, we reviewed the reference lists of the most rele-
vant articles.
We then adapted a randomised phase II design to in-
clude an early safety decision rule during the prime phase
of vaccine 1. We evaluated two types of statistical ap-
proaches for the safety decision rule: (1) a fixed-sample
rule from a frequentist perspective; and (2) a continuous
safety monitoring approach from a Bayesian perspective.
Simulation studies were built to evaluate the statistical
properties of the design with either decision rule. For each
simulation scenario under different underlying safety and
immunogenicity hypotheses, the participant outcomes for
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design) were drawn from independent binomial distribu-
tions of the binary safety and immunogenicity endpoints
respectively, and repeated in 10,000 simulation runs. We
also performed ancillary simulation studies based on
draws of participant outcomes from multinomial distribu-
tions, with specified joint probabilities of the two end-
points (corresponding to positive correlations from 0.1 to
0.5 between immunogenicity response and occurrence of
vaccine-related toxicity events) [42], while keeping the mar-
ginal proportions of the endpoints constant. Recruitment
dynamics were not taken into account for the simulation
studies. Simulations were performed with R software, ver-
sion 2.13.0 (The R Foundation, Vienna, Austria).
Furthermore, we projected the expected dynamics of
recruitment into the trial and the gain in timelines of
the clinical development plan by the proposed design
based on our previous experience setting up and con-
ducting HIV vaccine trials in France [32,43,44].Results and discussion
We adapted a randomised phase II design by including
two different types of early safety decision rules. We first
describe the characteristics of the proposed design with
each safety decision rule and its practical implications. We
then discuss potential alternative designs as well as poten-
tial limitations of our design and further perspectives.Characteristics of the proposed optimised phase I/II
design
We propose a randomised four-arm phase I/II design with
two independent binary endpoints for safety and immuno-
genicity, including a safety decision rule for vaccine 1 dur-
ing the prime vaccination phase in arm 1 (Figure 1). The
design is optimised in terms of a seamless transition from
phase I to phase II and allows for a parallel, unbiased
evaluation of several vaccine strategies in phase II.
The proportion of immunogenicity responders in each
arm is assessed by a standardised interferon-gamma (IFN-γ)
enzyme-linked immunospot (ELISPOT) assay at week 30,
that is, 2 weeks after the last vaccine immunisation. There is
a broad scientific consensus that a successful vaccine to pre-
vent HIV transmission must be able to elicit both HIV-
specific T-cells and antibodies responses [45,46]. Although
previous research has shown that a positive IFN-γ ELI-
SPOT response does not necessarily predict a protective
vaccine effect against HIV acquisition [47], it is assumed
that the IFN-γ ELISPOT response is at least a marker that
the vaccine has some effect on the T-cells of the immune
system. Under this assumption, the IFN-γ ELISPOT
should allow to screen for vaccine immunogenicity and
therefore seems adequate as a criterion to identify
non-immunogenic vaccine strategies that do not elicitany cellular response [19]. Additional immunogenicity
markers will be assessed as secondary endpoints.
Each arm of the phase II design has a single-stage
Fleming design for the binary immunogenicity endpoint
[48], comparing the proportion P of participants with a
positive IFN-γ ELISPOT response to a theoretical un-
acceptable proportion of 50%. The randomised design
with parallel arms is thus not intended for formal
between-arm comparisons but to limit heterogeneity in
volunteer characteristics between arms. In contrast with
the randomised phase II selection designs used in oncol-
ogy [14], this design does not aim to select one single
strategy (that is, the ‘best’ strategy) at the end of the
phase II design but retains all strategies with responses
above a minimal level. The decision rule is formulated
per arm and does not depend on the number of parallel
arms in the trial, which distinguishes its operating char-
acteristics from those of randomised phase II selection
designs [49]. The sample size of n = 23 per arm was de-
termined from published sample size tables based on
exact binomial distributions, with 90% power, one-sided
type I error rate of 5%, p1 of 80% (target proportion of
IFN-γ ELISPOT responders), and p0 of 50% (unaccept-
ably low proportion of IFN-γ ELISPOT responders) [50].
The integrated phase I evaluation of vaccine 1 is based
on an independent binary safety endpoint at week 2 in
arm 1, evaluating the proportion of participants without
any grade 3 or 4 clinical or biological adverse events re-
lated to vaccine 1 immunisation, reported from week 0
to week 2. Event relatedness will be reviewed and grades
validated by the Endpoint Review Committee.
We evaluated two types of safety decision rules, with
the aim to avoid exposure of additional participants to
an unsafe vaccine during the vaccine boost phase.
First, we considered a frequentist fixed-sample ap-
proach, which was also derived from a single-stage
Fleming design, with 90% power, one-sided type I error
rate of 5%, p1 of 95% (target proportion of participants
without any vaccine-related adverse event), and p0 of
70% (unacceptably low proportion of participants with-
out any vaccine-related adverse event). Based on the
proportion at which the lower bound of the one-sided
exact 95% confidence interval includes p0, this translates
into the following safety decision rule for vaccine 1 [50]:
if more than two out of the first 19 participants in arm 1
experience a vaccine-related adverse event by week 2,
then all vaccine 1 injections will be stopped.
Second, we studied a Bayesian sequential safety moni-
toring approach, allowing (1) for formally incorporating
the previously available knowledge about the safety of
MVA vectors in the prior distribution, and (2) for con-
tinuously updating the posterior distribution after each
participant or observed event during the trial [51]. We
used an enthusiastic prior distribution (Beta (6, 0.3)) to
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this vector type. The Bayesian safety decision rule was
then defined based on the posterior probability that the
proportion of participants without any vaccine-related
adverse event is below the target proportion of 0.95. At
any sequential analysis, the injections of vaccine 1 would
be stopped if this posterior probability was greater than
95% (Prob (Psafe < 0.95|data) > 0.95).
Given the planned rapid accrual dynamics of the
trial, the proposed safety decision rules do not aim at
halting enrolment, which may be completed before
the decision rule applies. Thus, the decision rule is
not necessarily expected to impact the number of vol-
unteers enrolled. Rather, it aims at taking a go/no-go
safety decision before the start of the vaccination
boost phase at week 20 to avoid exposing additional
participants to vaccine 1 in the other trial arms. If ad-
ministrations of vaccine 1 are stopped, arms 1 and 2
are halted but arms 3 and 4 continue, with partici-
pants in arm 4 receiving boost injections of vaccine 2
instead of vaccine 1.
Simulation results for each of the two safety decision
rules are shown in Table 1.
Table 2 summarises the combined operating character-
istics of a trial arm in the final phase I/II design, includ-
ing both the frequentist analysis of the immunogenicity
endpoint at week 30 as well as the continuous Bayesian
monitoring of the safety endpoint at week 2. The simu-
lated operating characteristics were satisfactory under all
combinations of the hypotheses for safety and immuno-
genicity respectively, with a maximum overall error rate
of 12.1%.
Equivalent simulations of the combined operating
characteristics of the design including the frequentist
fixed-sample safety decision rule showed relatively
similar results, albeit with a slightly higher maximum
overall error rate (overall probability of erroneous
conclusion 14.2% for the scenario with simulated
safety and efficacy proportions of 0.95 and 0.80,
respectively).Table 1 Comparison of operating characteristics of the two ty
Type of safety decision rule
Vaccine safe (Psafe = 0.95)
Probability of stopping Pro
Fixed-sample frequentist rule at n = 19 0.07
Continuous Bayesian monitoring 0.05
Fixed-sample frequentist rule: Interim analysis after 19 participants. Vaccine conside
val of observed proportion ≤0.7 for safety endpoint.
aIn a strict application of the fixed sample-design the decision rule only applies wh
rule was handled more flexibly (that is stopping as soon as a third participant expe
inator), stopping would occur after nine participants in median (IQR 6-12).
Continuous Bayesian monitoring of the safety endpoint: Sequential analysis after ea
the posterior probability that the vaccine is below the target level (Psafe <0.95) excAdditional simulations for scenarios with an inter-
mediate safety proportion of 80% and the fixed-
sample frequentist decision rule or the continuous
Bayesian decision rule showed probabilities of carry-
ing the vaccine forward to the next step of the devel-
opment plan in between those observed in the
simulations with a safety level of 70% and 95%,
respectively.
Introducing slight to moderate correlations between
immunogenicity response at week 30 and vaccine-
related adverse events at week 2 in the simulations did
not change the operating characteristics. This is due to
the fact that the endpoints are based on the marginal
proportions, which were kept constant by design of the
simulations.
Practical implications of the proposed design
As illustrated in Figure 2, compared with separate phase
I and II trials, the proposed design with either safety de-
cision rule allows for an estimated gain of approximately
12 months in the timelines of the clinical development
plan.
In terms of trial logistics and data management, to be
able to apply either of the decision rules in a timely
manner, the proposed design requires real-time monitor-
ing and validation of vaccine-related grade 3 and 4 ad-
verse events until week 2.
The frequentist fixed-sample safety decision rule is
stringent but requires high early accrual dynamics in order
to have 19 evaluable participants at week 2 in arm 1 before
any other participant reaches week 20 (first boost injection
of vaccine 1). By using a continuous monitoring approach
after each participant, the Bayesian rule allows for more
flexibility and can be applied even if accrual dynamics de-
viate from the initial projections. This may for instance be
the case if a certain time lag between the enrolment of the
first couple of volunteers is desired in order to not expose
several persons at once to a vaccine being first adminis-
tered in human. Moreover, the Bayesian method allows
for a direct interpretation of posterior probabilities.pes of safety decision rules
Simulation scenario
Vaccine unsafe (Psafe = 0.7)
bability of stopping Participant number at stop (median; IQR)
0.95 19 (19-19)a
0.96 8 (4-12)
red unsafe at interim if lower bound of one-sided exact 95% confidence inter-
en the outcome of 19 participants has been observed. If the application of the
riences an vaccine-related grade 3 or 4 adverse event, regardless of the denom-
ch participant or event. Vaccine considered unsafe at the first analysis where
eeds 95%. Enthusiastic prior: beta (6,0.3).
Table 2 Combined operating characteristics of the design including a frequentist efficacy evaluation and the
continuous Bayesian safety decision rule
Simulation scenario Proportion of outcomes in 10,000 simulations of one trial arm (%)












Unsafe (0.70) Inefficacious (0.50) 95.5 4.2 0.3 4.5
Unsafe (0.70) Efficacious (0.80) 95.6 0.3 4.1 4.7
Safe (0.95) Inefficacious (0.50) 4.8 91.4 3.8 8.6
Safe (0.95) Efficacious (0.80) 5.3 6.8 87.9 12.1
Simulation methods: Simulation of independent binomial distributions for safety and efficacy, respectively. Simulation of participant outcomes for one trial arm
with continuous Bayesian monitoring of the safety endpoint, repeated in 10,000 trial simulations per simulation scenario.
Bayesian continuous monitoring of the safety endpoint. Decision rule for safety outcome: Vaccine considered unsafe at the first analysis where the posterior probability
that the vaccine is below the target level (Psafe <0.95) exceeds 95%. Enthusiastic prior: beta (6,0.3).
Fixed-sample frequentist analysis of immunogenicity endpoint with 23 participants: conclusion that vaccine strategy is efficacious at final analysis if lower bound
of one-sided exact 95% confidence interval of observed proportion >0.5. Proportion of trials with erroneous outcomes shown in bold. The overall risk of erroneous
conclusion corresponds to the sum of erroneous trial outcomes.
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quentist estimate of the proportion of participants with
severe vaccine-related adverse events throughout the
whole follow-up in the trial (week 30), planned as a sec-
ondary safety endpoint, may be biased in the final ana-
lyses. If the final analysis stage is done from a frequentist
perspective, specific methods for an unbiased estimation
will thus need to be considered in order to take into ac-
count the fact that the final estimation is conditional on
not stopping before [52].Figure 2 Gain in timelines with optimised phase I/II design comparedAlternative existing designs
Most alternative phase I or II designs available in the lit-
erature were not further considered due to the specific
requirements for our trial design (see list of design re-
quirements above and Table 3).
We gave thorough consideration to alternative designs
to evaluate the safety of vaccine 1 within a phase II trial
but ruled them out for the following reasons:
Continuous toxicity monitoring approaches from
the frequentist perspective, such as those suggested byto separate phase I and II trials.
Table 3 Frequentist early-stage designs described in the literature and requirements for the vaccine trial design
Relevant features of the vaccine trial




























Potential alternative frequentist designs
Type Example
A) Designs for both efficacy and toxicity evaluation
Non-comparative bivariate
two-stage designs
Bryant and Day design [53] No No No
Seamless phase I/II design Design proposed by Messer et al.
(including a 3 + 3 design for the
integrated phase I evaluation) [54]
No No
B) Toxicity stopping rules integrated in efficacy designs
Non-comparative stopping rule based
on continuous toxicity monitoring per
serious adverse event
Continuous monitoring proposed
by Kramar et al. [55]
No
Non-comparative stopping rule based
on continuous toxicity monitoring per
participant
Continuous monitoring proposed
by Ivanova et al. [56]
No
Non-comparative stopping rule based
on group-sequential approach
Probabilistic approach proposed
by Yu et al. [57]
No
C) Designs for efficacy evaluation, considered in combination
with toxicity stopping rules in B)
Non-comparative two-stage or
multi-stage designs





Ranking design by Simon [35] No No
Comparative multi-arm designs Comparative phase II designs;
screening designs [60]
No No
Group sequential designs; adaptive
designs with comparative decision
rule [61]
No No No
Non-exhaustive list of trial features and alternative frequentist designs. Only main features of vaccine trial leading to incompatibility with alternative designs are indicated.
No: characteristic of the vaccine trial not compatible with alternative design.
The term ‘non-comparative’ is used to indicate that no inter-arm comparison is required.
aNo single validated endpoint in HIV vaccine immunogenicity trial, since correlates of vaccine protection are unknown. Currently, multiple different immunogenicity measurements are of interest without any definite
hierarchical order in their relevance (multidimensional data) and no obvious definition of a composite endpoint. In the present vaccine trial, the primary immunogenicity endpoint is only used as a screening assay to
discard out non-immunogenic strategies.
bImmunogenicity measurements done in batch on frozen samples at the end of the trial.
cSafety evaluation at week 2; Efficacy evaluation at week 30.
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[42,55,56,62] require that the participants (or events)
be observed sequentially (that is, one by one), which
is not granted with high accrual dynamics. An alter-
native approach to Bayesian continuous safety moni-
toring could have been designed based on the
predictive probability instead of the posterior distri-
bution. In the context of efficacy monitoring with
slightly higher maximum sample sizes than in our de-
sign it has been shown to have similar operating
characteristics than the method based on the poster-
ior distribution [63]. However, applying decision rules
based on future probabilities to a safety endpoint is
conceptually less intuitive, and we believe that a rule
based on the current posterior distribution better re-
sembles the decision making process for safety. For
the same rationale, we did not pursue the approach
published by Yu et al. who suggested toxicity moni-
toring based on a probabilistic approach estimating
the future rate of toxicity [57].
Most existing bivariate two-stage designs for com-
bined safety and efficacy evaluation, be they frequen-
tist or Bayesian [53,64-67], were developed in the
context of cytotoxic cancer drug development and
generally require both the efficacy and the safety out-
come to be observed and analysed with the same tim-
ing. This is not the case in our vaccine trial where
the immunogenicity outcome is measured in batch at
the end of the trial. Although a group-sequential bi-
variate design with increased flexibility, accommodat-
ing different schedules for efficacy and safety analyses
was also suggested, this design still requires at least
one analysis time including both safety and efficacy
endpoints [68].
Lastly, we considered the seamless phase I/II frequen-
tist design proposed by Messer et al. [54], the rationale
of which is very close to ours. However, their design is
appropriate for a single-arm trial, using a 3 + 3 enrol-
ment scheme in phase I, but is too complex to imple-
ment in the context of a multi-center multi-arm trial
and is not compatible with the accrual dynamics ex-
pected for the healthy volunteers in our trial. Other
seamless phase I/II designs comprising a dose-finding
phase have the same limitations for application in our
context [69].
Limitations of the proposed design
The design we propose fulfils all our specified require-
ments but has some limitations.
First, the set-up of a combined phase I/II design is
resource-efficient under the assumption that vaccine 1 is
safe, but is less efficient if vaccine 1 injections were
stopped for insufficient safety. However, even if this is
the case, two arms will still continue the trial (arms 3and 4, then both receiving the same vaccine strategy
with vaccine 2 as boost injections and merged together
for the final analysis). This will double the number of
participants receiving the strategy with vaccine 3 prime and
vaccine 2 boost and result in increased precision for the
non-comparative statistical analysis of this strategy. Thus,
even if vaccine 1 is stopped, at least some resource-
efficiency of the proposed four-arm trial will be maintained.
However, the proposed design would be less efficient in a
context, in which the safety record of the vaccine candidate
is more uncertain.
Second, the proposed design does not include a fur-
ther transition into the next development phases, and a
separate phase II follow-up trial will be necessary to
evaluate the immunogenicity spectrum of the vaccine
strategies with more precision.
Third, albeit randomised, our trial is not designed for
inter-arm comparisons. Investigators should be careful
about making indirect comparisons of the point esti-
mates in the different arms without considering preci-
sion [70].
Lastly, no multiplicity adjustment is planned in our
design to account for the multiple trial arms. However,
the control of false-positive selection for immunogenicity
(type I error) is not a major concern in this early-stage
trial, since independent follow-up trials are scheduled in
the clinical development plan.
Further perspectives in the clinical development plan
Set-up of a HIV vaccine trial using the design with the
Bayesian safety decision rule and including a 24-hour lag
between the enrolment of the first 20 volunteers is cur-
rently ongoing in a protocol of the French Vaccine Re-
search Institute (VRI).
At the end of this trial it is planned to carry all im-
munogenic and safe vaccine strategies forward to further
evaluations in another phase II immunogenicity trial,
since more data should be collected before deciding to
set up a large scale phase IIB/III trial with an HIV-
acquisition endpoint. However, unless the knowledge
about immunological correlates of protection and surro-
gate makers evolves substantially, it will remain difficult
to predict protective vaccine efficacy on the basis of
phase II immunogenicity results and the decision to
move the clinical development to a phase IIB/III trial
will be delicate. A group-sequential phase IIB/III design
could thus be envisaged, with interim looks at the HIV-
acquisition endpoint to allow for early stopping of strat-
egies for lack of efficacy or harm [17].
Conclusions
We used a pragmatic approach to design an optimised
randomised phase I/II trial for the evaluation of the
safety and immunogenicity of several HIV vaccine
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fixed-sample or Bayesian continuous early safety deci-
sion rule and allows for data integration of phases I and
II for the final analysis. Therefore, acceleration of early
clinical development of HIV vaccine strategies is, to
some extent, possible, but requires thoughtful planning
at the design stage. Validation of surrogate markers for
HIV vaccine efficacy will be crucial for the implementa-
tion of more complex adaptive phase II designs.
During the HIV vaccine development process, candi-
date vaccines are often improved in terms of the antigen
inserts used. The situation where a well-known vector
with a modified insert is administered first in humans
without dose escalation is thus not unusual in HIV vac-
cine development portfolios. Similar thoughts may also
apply to vaccine research for other diseases requiring
complex vaccine strategies, for example, malaria vac-
cines. Although some aspects discussed in this article
are specific to HIV vaccine research, the suggested early-
phase design could therefore also be useful for the clin-
ical development of other complex vaccine portfolios
with similar methodological requirements.
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